Ichthyosis Panel

Vast majority of ichthyoses are inherited, but this condition may also develop in the setting of malignancy, autoimmune or infectious disease and nutritional deficiency. Generally severe ichthyosis is inherited in autosomal recessive manner and less severe ichthyosis and related disorders have X-linked recessive or autosomal dominant heritance. Ichthyosis is characterized by dry, scaling skin that may be thickened or very thin. The disease onset is usually at birth, or within the first year, and continues to affect the patient throughout their lifetime. Autosomal recessive congenital ichthyosis (ARCI) includes several forms of non-syndromic ichthyosis: lamellar ichthyosis, congenital ichthyosiform erythroderma and harlequin ichthyosis. Although most neonates with ARCI are collodion babies, severity of ARCI vary significantly from harlequin ichthyosis, the most severe and usually fatal form, to lamellar ichthyosis and congenital nonbullous ichthyosiform erythroderma. Infants with harlequin ichthyosis are often born prematurely and are encased in thick, hard, armor-like plates of cornified skin that severely restrict movement. The skin affision may lead to dehydration, infections, chronic blistering, overheating and rapid-calorie loss. Autosomal dominant ichthyosis, also called as bullous congenital ichthyosiform erythroderma or epidermolytic hyperkeratosis, is generally mild, later onset disease (no presentation as collodion baby) restricted to itching and psychological impact of having skin with an unusual appearance. Mutations in TGM1 explain 90% or more of severe lamellar ichthyosis and 34%-55% of all ARCI and ALOX12B and ALOXE3 genes are estimated to be involved in 17% of ARCI cases. Ichthyosis vulgaris (AD) and X-linked ichthyosis are the most common types of ichthyosis, with an estimated incidence of 1:250 births and 1:6,000 male births. ARCI including lamellar ichthyosis, congenital ichthyosiform erythroderma and harlequin ichthyosis has overall incidence of 1:200,000.

The target region for each gene includes coding exons and ±20 base pairs from the exon-intron boundary. In addition, the panel includes non-coding and regulatory variants if listed above (Non-coding variants covered by the panel). Some regions of the gene(s) may be removed from the panel if specifically mentioned in the ‘Test limitations” section above. If the test includes the mitochondrial genome the target region gene list contains the mitochondrial genes. The sequencing data generated in our laboratory is analyzed with our proprietary data analysis and annotation pipeline, integrating state-of-the art algorithms and industry-standard software solutions. Incorporation of rigorous quality control steps throughout the workflow of the pipeline ensures the consistency, validity and accuracy of results. Our pipeline is streamlined to maximize sensitivity without sacrificing specificity. We have incorporated a number of reference population databases and mutation databases including, but not limited, to 1000 Genomes Project, gnomAD, ClinVar and HGMD into our clinical interpretation software to make the process effective and efficient. For missense variants, in silico variant prediction tools such as  SIFT, PolyPhen,MutationTaster are used to assist with variant classification. Through our online ordering and statement reporting system, Nucleus, ordering providers have access to the details of the analysis, including patient specific sequencing metrics, a gene level coverage plot and a list of regions with suboptimal coverage (<20X for nuclear genes and <1000X for mtDNA) if applicable. This reflects our mission to build fully transparent diagnostics where ordering providers can easily visualize the crucial details of the analysis process.

We provide customers with the most comprehensive clinical report available on the market. Clinical interpretation requires a fundamental understanding of clinical genetics and genetic principles. At Blueprint Genetics, our PhD molecular geneticists, medical geneticists, and clinical consultants prepare the clinical statement together by evaluating the identified variants in the context of the phenotypic information provided in the requisition form. Our goal is to provide clinically meaningful statements that are understandable for all medical professionals regardless of whether they have formal training in genetics.

Variant classification is the cornerstone of clinical interpretation and resulting patient management decisions. Our classifications follow the ACMG guideline 2015.

The final step in the analysis is orthogonal confirmation. Sequence and copy number variants classified as pathogenic, likely pathogenic, and variants of uncertain significance (VUS) are confirmed using bi-directional Sanger sequencing or by orthogonal methods such as qPCR/ddPCR when they do not meet our stringent NGS quality metrics for a true positive call.

Our clinical statement includes tables for sequencing and copy number variants that include basic variant information (genomic coordinates, HGVS nomenclature, zygosity, allele frequencies, in silico predictions, OMIM phenotypes, and classification of the variant). In addition, the statement includes detailed descriptions of the variant, gene, and phenotype(s) including the role of the specific gene in human disease, the mutation profile, information about the gene’s variation in population cohorts, and detailed information about related phenotypes. We also provide links to the references, abstracts, and variant databases used to help ordering providers further evaluate the reported findings if desired. The conclusion summarizes all of the existing information and provides our rationale for the classification of the variant.

Identification of pathogenic or likely pathogenic variants in dominant disorders or their combinations in different alleles in recessive disorders are considered molecular confirmation of the clinical diagnosis. In these cases, family member testing can be used for risk stratification. We do not recommend using variants of uncertain significance (VUS) for family member risk stratification or patient management. Genetic counseling is recommended.

Our interpretation team analyzes millions of variants from thousands of individuals with rare diseases. Our internal database and our understanding of variants and related phenotypes increases with every case analyzed. Our laboratory is therefore well-positioned to re-classify previously reported variants as new information becomes available. If a variant previously reported by Blueprint Genetics is re-classified, our laboratory will issue a follow-up statement to the original ordering healthcare provider at no additional cost, according to our latest follow-up reporting policy.